Fiscal 2026 results improve on higher revenue and margins
Biotricity reported fiscal 2026 net loss attributable to common stockholders of $3.13 million, narrowing from $11.94 million a year earlier.
Revenue rose 16% to $16 million, lifting operating results to operating income of $1.69 million from an operating loss of $2.45 million.
Gross margin improved 4.4 percentage points to 81%, reflecting a higher mix of technology fees, which totaled $14.44 million.
Selling, general and administrative expense fell to $8.49 million from $10.86 million, while research and development expense increased to $2.76 million from $2.16 million.
Cash and cash equivalents were $149,789 at March 31, 2026, with a working capital deficit of $31.3 million.
BTCY•
